Business Context and Reporting Period
This Form 8-K filing by TNF Pharmaceuticals, Inc. (TNFA) covers the period ending September 30, 2024. The report primarily addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it references prior audit reports for the fiscal years ended December 31, 2023, and 2022, which noted that the company has experienced net losses and negative cash flows from operations.
Material Changes
- Resignation of Auditor: Morison Cogen LLP resigned as the independent registered public accounting firm on September 30, 2024. The resignation coincides with the firm's exit from providing audit services to publicly traded companies.
- Appointment of New Auditor: On October 3, 2024, the Audit Committee engaged Stephano Slack LLC as the new independent registered public accounting firm, effective immediately for the fiscal year ending December 31, 2024.
- Going Concern Warning: The prior auditor's reports for 2022 and 2023 included a separate paragraph raising substantial doubt about the company's ability to continue as a going concern due to net losses and negative operating cash flows.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. The primary risk highlighted is the "substantial doubt" regarding the company's ability to continue as a going concern, as previously disclosed in the financial statements for 2022 and 2023. The company confirmed there were no disagreements with the former auditor regarding accounting principles or audit scope.
Investor Verification Checklist
- Verify the company's current cash runway and liquidity status given the historical "going concern" warnings.
- Confirm the transition timeline and initial findings of the new auditor, Stephano Slack LLC.
- Review the most recent quarterly or annual financial statements (10-Q or 10-K) for detailed figures on net losses and negative cash flows.
- Check for any subsequent filings regarding capital raising efforts to address liquidity concerns.